Patents by Inventor Stefan Seeber

Stefan Seeber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20150175696
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 9, 2015
    Publication date: June 25, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg FERTIG, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20150158950
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 29, 2014
    Publication date: June 11, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Nikolaos DIMOUDIS, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Marlene Pickl, Carola Ries, Stefan Seeber
  • METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
    Publication number: 20150140683
    Abstract: Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 21, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Petra Rueger, Tilman Schlothauer, Stefan Seeber
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 8999327
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: April 7, 2015
    Assignee: Hoffman-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Pickl, Carola Ries, Stefan Seeber, Kerstin Krueger
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20150080556
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20150004166
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 1, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE
    Publication number: 20140370019
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 1, 2014
    Publication date: December 18, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 8900581
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: December 2, 2014
    Assignee: Hoffman-La Roche Inc.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Pickl, Carola Ries, Stefan Seeber, Kerstin Krueger
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20140336363
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Carola Ries, Stefan Seeber, Marlene Thomas
  • Antibodies against IL-18R1 and uses thereof
    Patent number: 8883975
    Abstract: The invention provides anti-IL-18R1 antibodies and methods of using the same.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: November 11, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Michael Brandt, Jens Fischer, Stefan Jenewein, Klaus Kaluza, Eileen Samy, Stefan Seeber
  • CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE
    Publication number: 20140315252
    Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 23, 2014
    Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
  • ANTIBODIES AGAINST HUMAN IL33R AND USES THEREOF
    Publication number: 20140302015
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: June 11, 2014
    Publication date: October 9, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • RAPID METHOD FOR CLONING AND EXPRESSION OF COGNATE ANTIBODY VARIABLE REGION GENE SEGMENTS
    Publication number: 20140302559
    Abstract: In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed E. coli cells.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Simone Hoege, Erhard Kopetzki, Dominique Ostler, Stefan Seeber, Georg Tiefenthaler
  • Antibodies against human IL33R and uses thereof
    Patent number: 8785153
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: July 22, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 8703130
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: April 22, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20130005949
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 3, 2011
    Publication date: January 3, 2013
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20120329997
    Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 3, 2011
    Publication date: December 27, 2012
    Inventors: Georg Fertig, Alexander Fidler, Klaus Kaluza, Marlene Thomas, Carola Ries, Stefan Seeber
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20120321627
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: August 9, 2012
    Publication date: December 20, 2012
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 8268314
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Antibodies against human IL33R and uses thereof
    Publication number: 20120213774
    Abstract: An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 23, 2012
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Fertig, Jens Fischer, Guy Georges, Klaus Kaluza, Valeria Lifke, Joerg Moelleken, Sonja Offner, Achal Pashine, Stefan Seeber